Targeting RSV with Vaccines and Small Molecule Drugs

Author(s): Heather M. Costello, William C. Ray, Supranee Chaiwatpongsakorn, Mark E. Peeples.

Journal Name: Infectious Disorders - Drug Targets

Volume 12 , Issue 2 , 2012

Become EABM
Become Reviewer

Abstract:

Respiratory syncytial virus (RSV) is the most significant cause of pediatric respiratory infections. Palivizumab (Synagis®), a humanized monoclonal antibody, has been used successfully for a number of years to prevent severe RSV disease in at-risk infants. However, despite intense efforts, there is no approved vaccine or small molecule drug for RSV. As an enveloped virus, RSV must fuse its envelope with the host cell membrane, which is accomplished through the actions of the fusion (F) glycoprotein, with attachment help from the G glycoprotein. Because of their integral role in initiation of infection and their accessibility outside the lipid bilayer, these proteins have been popular targets in the discovery and development of antiviral compounds and vaccines against RSV. This review examines advances in the development of antiviral compounds and vaccine candidates.

Keywords: Antiviral, attachment glycoprotein, fusion glycoprotein, respiratory syncytial virus, therapeutic, vaccine, antiviral drug

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 12
ISSUE: 2
Year: 2012
Page: [110 - 128]
Pages: 19
DOI: 10.2174/187152612800100143
Price: $58

Article Metrics

PDF: 11